Evogene Ltd. (NASDAQ: EVGN) is -8.72% lower on its value in year-to-date trading and has touched a low of $0.90 and a high of $10.24 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EVGN stock was last observed hovering at around $4.45 in the last trading session, with the day’s loss setting it -0.16% off its average median price target of $15.00 for the next 12 months. It is also 71.4% off the consensus price target high of $15.00 offered by 1 analysts, but current levels are 71.4% higher than the price target low of $15.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $4.29, the stock is -17.72% and -33.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing -3.60% at the moment leaves the stock 19.48% off its SMA200. EVGN registered 304.72% gain for a year compared to 6-month gain of 10.28%. The firm has a 50-day simple moving average (SMA 50) of $6.4444 and a 200-day simple moving average (SMA200) of $4.6405.
The stock witnessed a -26.92% loss in the last 1 month and extending the period to 3 months gives it a -2.72%, and is -21.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.89% over the week and 12.48% over the month.
Evogene Ltd. (EVGN) has around 143 employees, a market worth around $173.26M and $0.81M in sales. Distance from 52-week low is 376.67% and -58.10% from its 52-week high.
Evogene Ltd. (EVGN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Evogene Ltd. (EVGN) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Evogene Ltd. is expected to release its quarterly report on 06/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.18 with sales reaching $300k over the same period.The EPS is expected to grow by 16.90% this year, but quarterly earnings will post -3.80% year-over-year.
Evogene Ltd. (EVGN) Top Institutional Holders
21 institutions hold shares in Evogene Ltd. (EVGN), with 5.73M shares held by insiders accounting for 18.12% while institutional investors hold 29.21% of the company’s shares. The shares outstanding are 40.39M, and float is at 29.09M with Short Float at 2.94%. Institutions hold 23.92% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 4.59 million shares valued at $21.59 million. The investor’s holdings represent 12.59% of the EVGN Shares outstanding. As of Dec 30, 2020, the second largest holder is Waddell & Reed Financial Inc. with 2.76 million shares valued at $12.96 million to account for 7.56% of the shares outstanding. The other top investors are SilverArc Capital Management, LLC which holds 0.6 million shares representing 1.64% and valued at over $2.82 million, while Senvest Management LLC holds 1.30% of the shares totaling 0.47 million with a market value of $2.23 million.
Evogene Ltd. (EVGN): Who are the competitors?
The company’s main competitors (and peers) include 22nd Century Group Inc. (XXII) that is trading 285.60% up over the past 12 months and Compugen Ltd. (CGEN) that is 9.75% higher over the same period. Short interest in the company’s stock has fallen -61.58% from the last report on Feb 11, 2021 to stand at a total of 1.38 million short shares sold with a short interest ratio of 0.51.